MTX-531-001 Phase 1 Study in Advanced Solid Tumors

StatusNot Yet Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
MEKanistic Therapeutics, Inc.
1 trial monitored
See all monitored trials
Breast Cancer
5,455 trials monitored
See 306 trials at risk
Colorectal Cancer
3,405 trials monitored
See 162 trials at risk
Head & Neck Cancer
2,608 trials monitored
See 150 trials at risk
and 1 more disease
This is a first-in-human, Phase 1, open-label study evaluating MTX-531, an investigational dual EGFR/PI3K inhibitor, in adults with advanced solid tumors. The study will evaluate the safety and tolerability of MTX-531, determine the maximum tolerated dose and recommended Phase 2 dose, and assess how the drug is processed by the body and its preliminary anti-tumor activity.
Trial Details
NCT Number NCT07874880
Lead Sponsor MEKanistic Therapeutics, Inc.
Collaborators: Translational Drug Development
Conditions
(from sponsor)		 Solid Tumors (Phase 1), HNSCC, Endometrial Cancer, Her2-negative Metastatic Breast Cancer, Pan-RAS and BRAF Wild-type Advanced, Metastatic Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma
Related terms Colorectal Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck
Enrollment 71 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov